Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Factors affecting long-term survival after surgical resection of pancreatic ductal adenocarcinoma

´ëÇÑ¿Ü°úÇÐȸÁö 2011³â 81±Ç 6È£ p.394 ~ 401
À±°æ¿ø, ÇãÁø¼®, ÃÖµ¿¿í, Choi Seoung-Ho,
¼Ò¼Ó »ó¼¼Á¤º¸
À±°æ¿ø ( Yoon Kyoung-Won ) 
Sungkyunkwan University School of Medicine Department of Surgery

ÇãÁø¼® ( Heo Jin-Seok ) 
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Surgery
ÃÖµ¿¿í ( Choi Dong-Wook ) 
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Surgery
 ( Choi Seoung-Ho ) 
Sungkyunkwan University School of Medicine Department of Surgery

Abstract


Purpose: Some patients who undergo surgical resection of pancreatic cancer survive longer than other patients. The purpose of this study was to identify the factors that affect long-term survival after resection of histopathologically confirmed pancreatic ductal adenocarcinoma.

Methods: A single-center, retrospective study was conducted among 164 patients who underwent surgical resection of pancreatic cancer, between May 1995 and December 2004. The patient follow-up process was conducted via telephone survey and review of electronic medical records for at least 5 years or until death.

Results: We compared patients with long-term (¡Ã60 months, n = 19) and short-term survival (<60 months, n = 145). Resection margin status, differentiation of the tumor, tumor stage, pre-operative serum level of albumin, total bilirubin and carbohydrate antigen (CA) 19-9 level are related with survival difference (all factors, P < 0.05). Multivariate analysis revealed that a pre-operative serum total bilirubin level <7 mg/dL and a pre-operative serum CA19-9 level <37 U/mL is a statistically significant prognostic factor for long-term survival.

Conclusion: The preoperative serum total bilirubin and serum CA19-9 levels are associated with long-term survival after surgical resection of pancreatic cancer.

Å°¿öµå

Pancreatic neoplasms; Bilirubin; CA19-9 antigen

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS